Rudolph W. Lucek

AkaRx, Inc. engages in the develop and manufacture of biopharmaceutical products for applications in hematology and therapeutic treatments for clinical-stage cancer. It offers thrombocytopenia treatment avatrombopag. The company was founded by Robert E. Desjardins and Donna Tempel in 2005 and is headquartered in NJ.

Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT.

Kanisa Pharmaceuticals, Inc. develops pharmaceuticals and provides medical services. The company develops drugs for diagnosis and treatment of cancer. It was founded by David A. Socks and is located in San Diego, CA.

Wyeth Holdings LLC manufactures and distributes chemicals. The firm's chemical contains phosphate rock, calcium, lime, carbide and nitrogen which are used in fertilizers. The company was founded by Frank Washburn in 1907 and is headquartered in Wayne, NJ.

Gilead Colorado, Inc. is a biopharmaceutical company that develops and markets drugs used for cardiovascular disorders. Their products include discovery of novel therapies and product identification and acquisition. The company was founded in 1996 and is headquartered in Westminster, CO.

Part of Pfizer Inc., Lederle Laboratories is a company that provides testing services. The company is based in Pearl River, NY.

BioTransplant, Inc. is a life science company. The company discovers, develops and commercializes therapeutics, therapeutic devices and therapeutic regimens designed to suppress undesired immune responses and enhance the body's ability to accept donor cells, tissues and organs. The company was founded on March 20, 1990 and is headquartered in Charlestown, MA.

EpicentRx, Inc. develops compounds sourced and adapted from the aerospace industry for treating cancer. Its technology includes chemical platform, RRx-001 overview, rons potential, epigenetics, collaboration and immunotherapy. The company was founded by Susan J. Knox and Mark Bednarski and is headquartered in Mountain View, CA.

Potenza Therapeutics, Inc. develops oncology programs and mechanisms for tumors detection. It is focusing on the discovery and development of novel immune-oncology therapeutics: molecules that stimulate the power of the immune system to fight cancer. The company was founded by Drew M. Pardoll and Daniel J. Hicklin in 2014 and is headquartered in Cambridge, MA.

Integrated Diagnostics, Inc. operates as a molecular diagnostics firm. It develops diagnostics and measurement technologies that has a capability of measuring biomarkers for diagnosis and management of complex diseases. The company was founded by Jim Heath, David J. Galas, Leroy E. Hood, and Paul Edward Kearney and is headquartered Seattle, WA.

Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA.

KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom.

Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA.

Idun Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the discovery and development of human therapeutics to control apoptosis. The company was founded by John C. Reed, Robert H. Horvitz, and Lawrence C. Fritz in March 1993 and is headquartered in San Diego, CA.

Tecan Genomics, Inc. provides genomics sample preparation solutions. It offers solutions which make biological samples accessible for genomic analysis. The firm has commercialized numerous proprietary DNA and RNA sample preparation products for use in research and diagnostic applications. The company was founded by Jan D'Alvise, James W. Larrick and Nurith Kurn in 2000 and is headquartered in San Carlos, CA.

Verinata Health, Inc. focuses on maternal and fetal health. It develop and offer non-invasive tests for early identification of fetal chromosomal abnormalities. The firm's products include 'verifi' prenatal test, a non-invasive test that detects three primary aneuploidies for trisomies 21, 18 and 13 from a single maternal blood draw as early as 10 weeks and 'Monosomy X', a test for Turner syndrome. The company was founded by Michael D. Grisham and Richard P. Rava in 2001 and is headquartered in San Diego, CA.

Xoft, Inc. develops Electronic Brachytherapy systems for radiation therapy applications. Its products include the Axxent Controller, which utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed; Axxent HDR X-ray Source, a low energy radiation treatment without the use of radioactive isotopes; Axxent Applicators, which provides a channel for the Axxent X-ray Source to deliver high dose rate, low energy radiation directly to the targeted area; and Axxent Accessories, an accessory product line designed to support and aid a physician during a procedure or treatment of cancer radiation. The company was founded by Michael Forman in 1998 and is headquartered in San Jose, CA.